NASDAQ · Drug Manufacturers - Specialty & Generic

Acorda Therapeutics, Inc. (ACOR) Stock

$0.66 -24.02% NASDAQ: ACOR Healthcare

Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States.

Valuation

MetricValue
Price$0.66
Market Cap$821028
P/E Ratio0.00
P/B Ratio-0.01
P/S Ratio0.01
EPS (TTM)$-203.59
52-Week High$24.20
52-Week Low$0.61
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE786.07%
ROA-214.75%
ROCE21.14%
Gross Margin60.86%
Operating Margin-19.78%
Net Margin-214.95%
Debt/Equity-1.21
Current Ratio0.33

Annual Financials (USD)

Metric20192020202120222023
Revenue$192.0M$153.0M$129.0M$119.0M$118.0M
Operating Profit$15.0M$-87.0M$-77.0M$-42.0M$-23.0M
Net Profit$-273.0M$-100.0M$-104.0M$-66.0M$-253.0M
EPS$-689.42$-246.40$-195.75$-66.90$-203.59
Op Margin7.6%-56.8%-59.9%-35.5%-19.8%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$800.0M$633.0M$455.0M$396.0M$118.0M
Total Liabilities$489.0M$395.0M$304.0M$302.0M$276.0M
Cash$62.0M$71.0M$46.0M$38.0M$30.0M
Borrowings$250.0M$260.0M$191.0M$173.0M$191.0M

Latest News

Acorn Secures 100% Ownership of OmniMetrix Subsidiary via Purchase of Remaining 1% Stake GlobeNewswire · Aug 18, 2026 Acorn Stock Slips Post Q2 Earnings, Revenues Decline Y/Y Zacks · Aug 10, 2026 Acorn Energy Inc (ACFN) (Q2 2026) Earnings Call Highlights: Monitoring Growth and Strategic ... GuruFocus.com · Aug 8, 2026 Acorn’s Q2 EPS of $0.12 Reflects Increasing High-Margin, Recurring Monitoring Revenue; Growth Initiatives Include New Generator Partnership and OMNI360 Launch GlobeNewswire · Aug 6, 2026 Acorn – Provider of Monitoring and Control Solutions for Mission-Critical Assets Hosts Q2 Earnings Call Thursday Aug. 6th at 11am ET GlobeNewswire · Jul 31, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-128.0M$-61.0M$-41.0M$-21.0M$-14.0M
Investing Cash Flow$-91.0M$119.0M$148.0M$0$-1.0M
Financing Cash Flow$-61.0M$-2.0M$-70.0M$0$0
Net Cash Flow$-189.0M$-2.0M$-38.0M$-21.0M$-14.0M
Free Cash Flow$-219.0M$-65.0M$-42.0M$-21.0M$-14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.80
FCF Yield-1735.39%
Quick Ratio0.26
Interest Coverage-0.74
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
GRYNGreen Hygienics Holdings Inc. $0.00 — 0.00 $44 0.00%
HPCOHempacco Co., Inc. $0.00 — 0.00 $1185 0.00%
LSDILucy Scientific Discovery Inc. $0.51 -23.29% -0.72 $906910 0.00%
MNKKQMallinckrodt plc $0.02 +0.00% 0.00 $0 0.00%
NBGVNewBridge Global Ventures, Inc. $0.00 — — $769176 0.00%

About Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing treatments for conditions affecting the nervous system, primarily within the United States. Its current product offerings include Ampyra (dalfampridine), an oral medication prescribed to enhance walking ability in individuals with multiple sclerosis (MS). The company also distributes Inbrija in Europe, which is used to manage "OFF" periods experienced by Parkinson's disease patients. Globally, Ampyra is recognized and sold as Fampyra across Europe, Asia, and the Americas. Beyond its existing products, Acorda is actively advancing several experimental therapies: ARCUS for the management of acute migraine attacks, rHIgM22 which has successfully completed Phase I clinical trials for MS, and Cimaglermin alfa, currently being investigated for patients with heart failure. The company holds a licensing and collaborative agreement with Biogen Inc. for the ongoing development and market distribution of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and operates from its headquarters in Ardsley, New York.

Acorda Therapeutics, Inc. is headquartered in US.

Acorda Therapeutics, Inc. (ACOR) stock trades at $0.66 with a market capitalization of $821028. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of -0.01, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.61 and $24.20, and currently trades 97.3% below its 52-week high.

On profitability, Acorda Therapeutics, Inc. generates a return on equity (ROE) of 786.07% — well above the market average, a sign of a high-quality business, return on capital employed of 21.14%, an operating margin of -19.78%, a net profit margin of -214.95%.

Official website: www.acorda.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1170.74 +0.10% JNJ Johnson & Johnson $259.53 +1.19% ABBV AbbVie Inc. $275.22 +1.03% MRK Merck & Company, Inc. Common Stock (new) $145.01 +1.85% UNH UnitedHealth Group Incorporated Common Stock (DE) $374.45 +0.94% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $656.26 +0.66% AMGN Amgen Inc. $410.76 +0.82% GILD Gilead Sciences, Inc. $149.60 +1.70% ABT Abbott Laboratories $99.59 +1.12% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides